Gilead Sciences (GILD) closed the latest trading day at $76.49, indicating a +0.57% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 1.37%. Elsewhere, the Dow saw a downswing of 1.21%, while the tech-heavy Nasdaq depreciated by 2.3%.Coming into today, shares of the HIV and hepatitis C drugmaker had gained 14.22% in the past month. In that same time, the Medical sector gained 0.74%, while the S&P 500 gained 1.11%.Analysts and investors alike will be keeping ...

Lubo Ivanko/iStock Editorial via Getty Images Gilead Sciences (NASDAQ:GILD) has dropped 15% YTD substantially underperforming the market. We last discussed the company two months, discussing how it was turning itself around. The company was impacted by tough trial results from Trodelvy, another disappointment given the more than $20 billion acquisition of Immunomedics. Despite that, the company has the ability to utilize its assets to generate strong returns while supporting a >4% yield. Gilead Sciences ...

In the latest market close, Gilead Sciences (GILD) reached $72.41, with a -0.21% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. At the same time, the Dow added 0.32%, and the tech-heavy Nasdaq gained 1.58%.Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.67% over the past month. This has outpaced the Medical sector's gain of 0.31% and the S&P 500's gain of 0.43% in that time.Analysts and investors al ...

Industry Overview - The Nasdaq Biotechnology Index, which includes 215 biotech and pharmaceutical stocks, is up nearly 8% year-to-date, but this performance is less than half of the Nasdaq 100 [1] - The index has historically experienced long upcycles, gaining 341% from August 2011 to July 2015, and it has increased 33% since late October 2023 [1] Company Analysis: Gilead Sciences (GILD) - Gilead Sciences has a market capitalization of $91.6 billion, with shares down over 9% in 2024 and only up 13% over the past five years [2] - The company is known for its Hepatitis C cure and HIV prevention, currently working on over 20 oncology treatments, aiming to be a top 10 oncology company by 2030 [2] - Biktarvy, its leading drug, generated $2.9 billion in Q1 2024, accounting for 43% of total revenue, with a 10% year-over-year increase [2][3] - Other significant drugs include Sofosbuvir and Velpatasvir for Hepatitis C ($405 million) and Veklury for Covid-19 ($555 million), with oncology revenue at $789 million, an 18% increase year-over-year [3] Company Analysis: Jazz Pharmaceuticals (JAZZ) - Jazz Pharmaceuticals has a market cap of $6.86 billion, with shares down 11% in 2024 and 20% over the past five years [4] - The company acquired GW Pharmaceuticals for $7.2 billion in 2021, known for its CBD-based drug Epidiolex, which saw a 5% revenue growth to $198.7 million in Q1 2024 [4] - Xywav, another key product, generated $315.3 million in Q1 2024, with both drugs accounting for 57% of total revenue [4] - Jazz expects 2024 revenues of $4.1 billion and adjusted earnings per share of $18.75, with shares trading at 5.8 times its EPS for 2024 [5] Company Analysis: Supernus Pharmaceuticals (SUPN) - Supernus Pharmaceuticals has a market cap of $1.60 billion, with shares up nearly 5% in 2024 but down 9% over the past five years [6] - The company specializes in CNS drugs, with Qelbree as its top-selling product, generating $45.1 million in Q1 2024, a 75% increase year-over-year [6] - Sales for Trokendi XR, a migraine treatment, fell 54% to $16.0 million due to loss of exclusivity, while Oxtellar XR also saw a 7% decline in sales [7] - Excluding the two drugs that lost exclusivity, Supernus's sales increased by 12% in Q1 to $100.7 million, with three out of four analysts rating the stock as a Buy [7]

These three dividend vehicles could provide reliable passive income.Dividend stocks can be dual-threat vehicles, offering investors the best of both worlds. Specifically, these equities can act as reliable passive income generators while simultaneously possessing the potential to increase your net worth through share-price appreciation.If you're interested in buying a handful of dividend stocks as part of a passive income strategy, consider investing $51,000 across these three attractive options: AT&T (T 1. ...

Gilead Sciences (GILD) closed the latest trading day at $71.64, indicating a +1.17% change from the previous session's end. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 1.85%, and the Nasdaq, a tech-heavy index, added 0.2%.Shares of the HIV and hepatitis C drugmaker have appreciated by 10.18% over the course of the past month, outperforming the Medical sector's gain of 0.71% and the S&P 500's gain of 3.82%.Analysts and investors alike will be keeping a close eye on the ...

As investors buy from tech giants like Nvidia, many other compelling opportunities exist for those looking for growth. Driven by innovation, revenue growth, and an enviable market position, each of these 3 underappreciated stocks offers investors a unique opportunity for profitability. All of them have shown clear signs of potentially growing by double-digit growth in the next few months.These stocks have been overlooked in an environment of modest gains in anticipation of the upcoming economy. However, loo ...

Key TakeawaysRaymond James analysts upgraded Gilead Sciences stock to "outperform" from "market perform."The upgrade was driven by Gilead's drug lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in women.Lenacapavir and PBC treatment seladelpar could see combined annual sales of $3.7 billion by 2030, according to Raymond James' model. Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “m ...

Biotech giant Gilead Sciences, Inc. (GILD) , a leader in HIV drugs, is having a tough run as recent pipeline setbacks disappointed investors and acquisition-related charges adversely impacted the bottom line. The stock has been under pressure owing to these challenges.While the company’s leading HIV franchise maintains momentum and its efforts to build an oncology franchise to diversify its portfolio are encouraging, the failure of late-stage studies evaluating oncology drug Trodelvy (sacituzumab govitecan) ...

Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 2% in pre-market trading, after Raymond James upgraded the stock to "outperform" from "market perform."  According to the the brokerage, GILD -- one of Schaeffer's top 2024 picks -- has support over the next five years from two key drug candidates that could increase revenue growth.Overall, analysts are pessimistic towards toward the security, with 14 of 24 covering firms recommending a "hold," and the stock's average 12-month price target stand ...